BioCina and NovaCina form strategic alliance

Microbial development and contract manufacturing companies Adelaide’s BioCina and Perth’s NovaCina have announced a strategic partnership to provide integrated drug substance and drug product solutions for the pharmaceutical sector.

The two companies are buy-outs from the Pfizer pharmaceutical company and share the same investor – private investment firm Bridgewest Group – and will now collaborate to offer full service development and contract manufacturing capabilities.

This alliance enables BioCina to offer the highest quality fill-and-finish solutions to their clients, to convert drug substances produced at their Adelaide facility into sterile injectable drugs at NovaCina’s advanced facility in Perth, Australia.

This collaboration marks a significant milestone in providing end-to-end biopharmaceutical manufacturing solutions to clients, according to a statement.

BioCina’s Chief Executive Officer and member of NovaCina board Mark W. Womack said: “BioCina is excited to partner with NovaCina, integrating our globally recognised expertise in clinical and commercial process development and drug substance manufacturing with their…drug product services.

“This partnership promises to deliver unparalleled quality, adherence to the highest regulatory standards, and on-time delivery of client programmes, setting a new benchmark in the market.”

BioCina delivers cell line development, process development, and cGMP drug substance manufacturing for microbial, pDNA and mRNA modalities.

NovaCina offers development, manufacturing, packaging, labelling, and stability studies.

NovaCina’s Chief Executive Officer Cyrus K. Mirsaidi said “Together, we provide a seamless end-to-end offering.

“At NovaCina, we are delighted to bring our world-class quality and safety to this value-adding collaboration.”

Picture: BioCina